Acadia Pharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022

Rhea-AI Summary

Acadia Pharmaceuticals (NASDAQ: ACAD) will present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 1:40 p.m. ET. The event will be held virtually, with a live webcast available on Acadia's website under the investors section. An archived recording will be accessible until March 18, 2022. Acadia focuses on neuroscience breakthroughs, having developed the first approved treatment for Parkinson’s disease psychosis and is advancing therapies for dementia-related psychosis and other CNS disorders.

SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 11^th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022, at 1:40 p.m. Eastern Time.

The conference will be held virtually. A live webcast of Acadia’s presentation will be accessible on the company’s website, www.acadia-pharm.com, under the investors section and an archived recording will be available on the website through March 18, 2022.

About Acadia Pharmaceuticals
Acadia is advancing breakthroughs in neuroscience to elevate life. For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson’s disease psychosis. Our late-stage development efforts are focused on treating psychosis in patients with dementia, the negative symptoms of schizophrenia and Rett syndrome. Our early-stage development efforts are focused on novel approaches to pain management, cognition and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia-pharm.com and follow us on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220211005092/en/

Media Contact:

Acadia Pharmaceuticals Inc.

Deb Kazenelson

(818) 395-3043

media@acadia-pharm.com

Investor Contact:

Acadia Pharmaceuticals Inc.

Mark Johnson, CFA

(858) 261-2771

ir@acadia-pharm.com

Source: Acadia Pharmaceuticals Inc.

FAQ

When is Acadia Pharmaceuticals presenting at the SVB Leerink Global Healthcare Conference?

Acadia Pharmaceuticals will present on February 18, 2022, at 1:40 p.m. Eastern Time.

How can I watch Acadia Pharmaceuticals' presentation at the conference?

A live webcast of Acadia's presentation will be available on their website under the investors section.

Until when will the presentation recording be available for Acadia Pharmaceuticals?

The archived recording of Acadia's presentation will be available until March 18, 2022.

What is Acadia Pharmaceuticals known for?

Acadia is known for developing the first approved therapy for hallucinations and delusions associated with Parkinson’s disease psychosis.

What areas is Acadia Pharmaceuticals focusing its late-stage development on?

Acadia is focusing on treating psychosis in dementia patients, negative symptoms of schizophrenia, and Rett syndrome.